Raymond James & Associates Sells 5,425 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Raymond James & Associates trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHRGet Rating) by 11.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 42,444 shares of the biotechnology company’s stock after selling 5,425 shares during the quarter. Raymond James & Associates owned about 0.09% of United Therapeutics worth $8,887,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. grew its position in United Therapeutics by 5.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 2,869 shares of the biotechnology company’s stock valued at $601,000 after purchasing an additional 141 shares during the last quarter. Eqis Capital Management Inc. grew its position in United Therapeutics by 4.4% during the 3rd quarter. Eqis Capital Management Inc. now owns 2,694 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 113 shares during the last quarter. Granite Investment Partners LLC grew its position in United Therapeutics by 0.6% during the 3rd quarter. Granite Investment Partners LLC now owns 28,807 shares of the biotechnology company’s stock valued at $6,032,000 after purchasing an additional 168 shares during the last quarter. Calamos Advisors LLC grew its position in United Therapeutics by 32.4% during the 3rd quarter. Calamos Advisors LLC now owns 2,947 shares of the biotechnology company’s stock valued at $617,000 after purchasing an additional 721 shares during the last quarter. Finally, Cardinal Capital Management grew its position in United Therapeutics by 1.4% during the 3rd quarter. Cardinal Capital Management now owns 7,903 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 109 shares during the last quarter. 95.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. Bank of America reaffirmed an “underperform” rating on shares of United Therapeutics in a report on Tuesday, September 20th. Argus raised their price target on shares of United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright raised their price target on shares of United Therapeutics from $255.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, November 3rd. Wedbush raised their price objective on shares of United Therapeutics from $250.00 to $305.00 in a report on Thursday, November 3rd. Finally, Morgan Stanley upped their target price on shares of United Therapeutics from $322.00 to $330.00 and gave the company an “overweight” rating in a report on Tuesday, December 6th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $283.64.

United Therapeutics Trading Down 0.8 %

Shares of UTHR stock opened at $261.56 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.39 and a current ratio of 9.68. The stock has a fifty day simple moving average of $271.11 and a two-hundred day simple moving average of $240.25. The firm has a market capitalization of $11.92 billion, a PE ratio of 17.79, a PEG ratio of 1.56 and a beta of 0.62. United Therapeutics Co. has a 52-week low of $158.38 and a 52-week high of $283.09.

United Therapeutics (NASDAQ:UTHRGet Rating) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.57 by $1.34. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. The firm had revenue of $516.00 million during the quarter, compared to analysts’ expectations of $492.92 million. On average, analysts predict that United Therapeutics Co. will post 16.63 EPS for the current fiscal year.

Insider Activity

In related news, EVP Paul A. Mahon sold 12,000 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the completion of the transaction, the executive vice president now owns 36,397 shares in the company, valued at $7,145,095.07. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other United Therapeutics news, EVP Paul A. Mahon sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $196.31, for a total transaction of $2,355,720.00. Following the completion of the transaction, the executive vice president now owns 36,397 shares in the company, valued at approximately $7,145,095.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Judy D. Olian sold 1,010 shares of the company’s stock in a transaction that occurred on Friday, December 9th. The stock was sold at an average price of $282.00, for a total value of $284,820.00. Following the sale, the director now directly owns 7,655 shares in the company, valued at $2,158,710. The disclosure for this sale can be found here. Insiders have sold a total of 175,390 shares of company stock worth $46,244,015 over the last quarter. Insiders own 12.40% of the company’s stock.

United Therapeutics Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.